Home › Trials › NCT02705846
Clinical trial Recruiting at 1 site Observational Ages 18 and up Men only

Analyzing outcomes in prostate cancer patients with rare genetic mutations

Official title: Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes

Run by Institute of Cancer Research, United Kingdom · NCT02705846 · Data updated 2026-11-12

This study is testing how prostate cancer patients with rare genetic mutations respond to treatment compared to those without these mutations to find better ways to manage their care.

More Prostate Cancer trials

Quick facts

Study typeObservational
Ages18 Years and up
SexMen only
Enrollment4260 (estimated)
SponsorInstitute of Cancer Research, United Kingdom
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Sutton, Surrey)
StatusRecruiting
StartedSeptember 2014
Main results expectedDecember 2030
Study endsDecember 2035
Registry record updatedOctober 29, 2026
Trial IDNCT02705846 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men diagnosed with prostate cancer who are either known carriers of specific germline mutations or non-carriers.

Probably not a fit

Patients under 18 years of age or those unable to provide informed consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

GENPROS aims to analyze the outcomes of prostate cancer patients who carry rare gene mutations, such as BRCA1, BRCA2, and those associated with Lynch Syndrome. The study includes a cohort of mutation carriers matched with a control group of non-carriers, collecting clinical data on treatment and outcomes both retrospectively and prospectively. Archived tumor samples will be collected for profiling, and participants may provide blood or saliva samples for genetic analysis. This research is crucial for informing clinical trials on the best management strategies for prostate cancer in high-risk patients.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies for prostate cancer in patients with genetic predispositions.

How similar studies have gone: Other studies have shown success in analyzing genetic factors in cancer outcomes, but this specific approach focusing on rare mutations in prostate cancer is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Men diagnosed with PCa are eligible if:
* known carriers of germline mutations associated with PCa risk OR
* known non-carriers of mutations in the genes above

Exclusion Criteria:

* patients under 18 years of age
* patients who are unable to give informed consent
* patients who cannot be traced (\<6 months follow-up) or whose clinical data are not available
* patients whose genetic status is unknown

Where it's running

  • Institute of Cancer Research and Royal Marsden Hospital
    Sutton, Surrey, United Kingdom     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Institute of Cancer Research, United Kingdom 22
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.